A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 1

Conditions

Coronavirus Disease 2019 (COVID-19)
Healthy Volunteer

Treatments

Drug: AZD7442 IM
Drug: Placebo IM
Drug: Placebo IV
Drug: AZD7442 IV

Study type

Interventional

Funder types

Industry

Identifiers

NCT05437289
D8850C00007

Details and patient eligibility

About

To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD7442 in Healthy Chinese Adults. vs. placebo

Full description

A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD7442 in healthy Chinese participants 18 to 55 years of age, approximately 60 participants will be randomised in a 4:1 ratio to either AZD7442 or placebo, administered by intramuscular (IM) injection or intravenous (IV) infusion, and approximately 479 days in duration for each participant.

Enrollment

61 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adults 18 to 55 years of age
  • Healthy by medical history, physical examination, and baseline safety laboratory tests
  • Negative results of both SARS-CoV-2 qRT-PCR and serology tests within 14 days prior to randomisation.
  • Contraceptive within 365 days post dosing

Exclusion criteria

Medical condition:

  • Known hypersensitivity to monoclonal antibody (mAb) or investigational product (IP) component.
  • Acute illness including fever on the day prior to or day of dosing.
  • Any other significant disease increase the risk to participant study.

Laboratory related:

  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > upper limit of normal (ULN), or alkaline phosphatase (ALP) or TBL (total bilirubin) > 1.5 × ULN
  • Serum creatinine > ULN
  • Haemoglobin < lower limit normal (LLN)
  • Platelet count < LLN
  • White blood cell or neutrophil count outside normal reference ranges
  • Other laboratory significantly abnormal in the screening panel that, in the opinion of the investigator, will increase participants risk or might confound analysis of study results.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

61 participants in 8 patient groups, including a placebo group

300 mg AZD7442 IM
Experimental group
Description:
Administration of a single dose of 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) sequentially by intramuscular (IM) injection.
Treatment:
Drug: AZD7442 IM
300mg placebo IM
Placebo Comparator group
Description:
Administration of placebo with dose match to AZD7442 in the same cohort sequentially by intramuscular (IM) injection.
Treatment:
Drug: Placebo IM
600 mg AZD7442 IM
Experimental group
Description:
Administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) sequentially by intramuscular (IM) injection.
Treatment:
Drug: AZD7442 IM
600mg placebo IM
Placebo Comparator group
Description:
Administration of placebo with dose match to AZD7442 in the same cohort sequentially by intramuscular (IM) injection.
Treatment:
Drug: Placebo IM
300 mg AZD7442 IV
Experimental group
Description:
co-administration of a single dose of 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) by intravenous (IV) infusion.
Treatment:
Drug: AZD7442 IV
Drug: AZD7442 IV
300mg placebo IV
Placebo Comparator group
Description:
co-administration of a single dose of placebo in equivalent volume by intravenous (IV) infusion.
Treatment:
Drug: Placebo IV
600 mg AZD7442 IV
Experimental group
Description:
co-administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by intravenous (IV) infusion.
Treatment:
Drug: AZD7442 IV
Drug: AZD7442 IV
600mg placebo IV
Placebo Comparator group
Description:
co-administration of a single dose of placebo in equivalent volume by intravenous (IV) infusion.
Treatment:
Drug: Placebo IV

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems